For the quarter ending 2025-09-30, TARS had $16,076K increase in cash & cash equivalents over the period. $16,347K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 433 |
| Net loss | -12,585 | -45,460 |
| Depreciation | 220 | 433 |
| Amortization of intangible assets | - | 500 |
| Amortization of intangible assets | 220 | 500 |
| Amortization of debt-related costs | 152 | 285 |
| Stock-based compensation | 12,243 | 15,163 |
| Loss on debt extinguishment | 0 | 0 |
| Non-cash lease expense | 205 | 323 |
| Net amortization/accretion of marketable securities | 1,534 | 3,023 |
| Realized loss on equity investments | 0 | 0 |
| Change in fair value of equity warrants issued by licensee | 0 | 0 |
| Unrealized (gain) loss from transactions denominated in a foreign currency | 12 | -26 |
| Accounts receivable, net | 14,286 | 11,574 |
| Inventory | -37 | 1,252 |
| Other receivables | -190 | 608 |
| Prepaid expenses | -7,978 | 14,449 |
| Other non-current assets | 373 | -227 |
| Accounts payable and other accrued liabilities | 23,842 | 13,603 |
| Accrued payroll and benefits | 1,940 | -4,212 |
| Other long-term liabilities | 0 | 0 |
| Net cash used in operating activities | 18,257 | -50,038 |
| Proceeds from maturities of marketable securities | 99,500 | 170,218 |
| Purchases of marketable securities | 102,333 | 255,273 |
| Purchases of long-term investments | 0 | 0 |
| Purchases of property and equipment | 1,910 | 1,591 |
| Net cash used in investing activities | -4,743 | -86,646 |
| Proceeds from issuance of common stock, net of paid issuance costs | 0 | 134,771 |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | 0 | 0 |
| Proceeds from sale of common stock under employee stock purchase plan | 0 | 1,101 |
| Proceeds from exercise of stock options | 2,562 | 2,642 |
| Proceeds from long-term debt | 0 | 0 |
| Payments for debt extinguishment | 0 | 0 |
| Payments of debt issuance costs | 0 | 0 |
| Net cash provided by financing activities | 2,562 | 138,514 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 16,076 | 1,830 |
| Cash and cash equivalents at beginning of period | 97,381 | - |
| Cash and cash equivalents at end of period | 115,287 | - |
Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. (TARS)